Complete response to nivolumab for metastatic renal cell carcinoma on hemodialysis patient; a case report

Publication date: Available online 15 October 2019Source: Urology Case ReportsAuthor(s): Akito Ito, Mizuki Hisano, Makoto Takahashi, Naoki Komine, Takaya Abe, Wataru ObaraAbstractA 73-year-old-male patient with hypertension and grade 3B chronic kidney disease underwent radical nephrectomy in the year 2000. As the renal function gradually worsened, the patient was started on hemodialysis in 2003. Eleven years after nephrectomy, the metastases were pointed out. The patient received sunitinib as first-line therapy. Thereafter, as the metastatic lesions became larger, we initiated nivolumab therapy (3 mg/m2 every 2 weeks). After 52 weeks, the metastatic lesions continued showing complete response (CR). No adverse effects were observed during nivolumab treatment.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research